Company Novus Therapeutics, Inc. Nasdaq
Equities
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 51 | 20-04-30 | |
Paul Little
DFI | Director of Finance/CFO | 60 | 21-03-14 |
Steven N. Perrin
PSD | President | 59 | 20-09-13 |
Eliezer Katz
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-22 |
John Herberger
CTO | Chief Tech/Sci/R&D Officer | - | 22-04-30 |
Bryan E. Smith
CMP | Compliance Officer | 45 | 21-04-18 |
David Hovland
LAW | General Counsel | - | 21-04-18 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Keith Katkin
CHM | Chairman | 52 | 17-04-30 |
Walter C. Ogier
BRD | Director/Board Member | 67 | 20-09-13 |
John S. McBride
BRD | Director/Board Member | 72 | 17-04-30 |
Steven N. Perrin
PSD | President | 59 | 20-09-13 |
Chief Executive Officer | 51 | 20-04-30 | |
James Robinson
BRD | Director/Board Member | 54 | 23-09-30 |
June Lee
BRD | Director/Board Member | 58 | 20-12-08 |
Jan Hillson
BRD | Director/Board Member | 71 | 21-07-01 |
Allan Kirk
BRD | Director/Board Member | - | 23-10-01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 110,086 | 0 | 0 | 94.57 % |
Stock B | 1 | 24,813,130 | 23,466,868 ( 94.57 %) | 0 | |
Stock C | 0 | 4,422 | 0 | 0 |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |